Zydus Cadila gets USFDA nod to make drug for treating dementia

Donepezil Hydrochloride Tablet, in the strength of 23 mg, used to treat dementia related to Alzheimer’s, will be marketed by Zydus Cadila in the wake of receiving the final approval from the USFDA. It will be manufactured at the group’s formulations manufacturing facility at Moraiya, Ahmedabad.
 
The group has more than 140 approvals and has so far filed over 300 ANDAs since the commencement of the filing process in FY 2003-04. Meanwhile, the stock was trading up by 2.08% at Rs 510.50 per share on the BSE at 1127 hours. It opened at Rs 502.75 per share and touched its intraday high and low at Rs 512.60 and Rs 502.55 per share.
 
The stock has attracted a total traded volume of 5,24,973 shares and traded value of Rs 2,674.89 lakh on the NSE at 1124 hours. The stock’s 52 week high stood at Rs 560 as on July 10, 2017 and low at Rs 328.80 per share as on December 23, 2016.